Ascendis Pharma A (ASND) Total Liabilities (2012 - 2026)

Ascendis Pharma A has disclosed Total Liabilities across 15 years of filings, most recently posting $1.8 billion for Q1 2026.

• Total Liabilities for Q1 2026 came in at $1.8 billion, up 34.79% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.8 billion (up 34.79% YoY), and the FY2025 annual result was $1.7 billion, up 24.2% from the prior year.
• Total Liabilities came in at $1.8 billion for Q1 2026 at Ascendis Pharma A, up from $1.7 billion in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $1.8 billion in Q1 2026 to a low of $767.2 million in Q2 2022.
• The 5-year median for Total Liabilities is $1.1 billion (2024), against an average of $1.2 billion.
• Across the five-year window, Total Liabilities jumped 303.36% in 2022 and increased 7.73% in 2023, its largest moves.
• Ascendis Pharma A's Total Liabilities stood at $843.1 million in 2022, then increased by 23.95% to $1.0 billion in 2023, then surged by 31.42% to $1.4 billion in 2024, then gained by 24.2% to $1.7 billion in 2025, then advanced by 4.0% to $1.8 billion in 2026.
• The last three Total Liabilities figures came in at $1.8 billion (Q1 2026), $1.7 billion (Q4 2025), and $1.6 billion (Q3 2025), per Business Quant data.